Similar companies
Income Statement (USD)
| Q4 '23 | QoQ | |
|---|---|---|
| Gross Profit | 140,000 | 105% |
| Cost of Revenue | -640,000 | 127.4% |
| Operating expense | -660,000 | 124.9% |
| Net Income | -17M | 19.7% |
| EBITDA | -16M | 18.6% |
Balance Sheet (USD)
| Q4 '23 | QoQ | |
|---|---|---|
| Total Assets | 5.5M | 433.6% |
| Total Liabilities | 96M | 26.2% |
| Shares Outstanding | 35M | 1.6% |
Cash Flow (USD)
| Q4 '23 | QoQ | |
|---|---|---|
| Cash from operations | -870,000 | 23.4% |
| Cash from financing | 840,000 | 56% |
EPS
Financial Highlights for Ocean Biomedical in Q4 '23
Gross Profit stood at 140,000, marking a 105% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was -640,000, a -127.4% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were -660,000, showing a -124.9% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -17M, showing a -19.7% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -16M, showing a -18.6% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Ocean Biomedical faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. A decline in EBITDA signals potential operational challenges or increased costs.
